Sutro Biopharma(STRO)

SOUTH SAN FRANCISCO, CAPharmaceutical4 H-1B visas (FY2023)

Focus: Sutro Biopharma is a public biotech company leveraging its proprietary Biochemical Protein Synthesis platform to develop oncology therapeutics, primarily antibody-drug conjugates (ADCs). The company operates as a mid-cap biotech with a focused pipeline in hematologic and solid tumors.

Oncology

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Recent layoff filing — 1 affected

9/29/2025 — Remote Remote CA 94080, CA · 1 affected · Layoff Amendment

Source: state DOL filings via Big Local News

About Sutro Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Sutro Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$62M

Pipeline & Clinical Trials

STRO-002

Ovarian Cancer

PHASE_1

Clinical Trials (1)

NCT05200364A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Phase 1

Help build intelligence for Sutro Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Platform-driven approach: proprietary protein synthesis technology enables differentiated ADC development with potential for multiple shots on goal across oncology indications
Accelerating pipeline: Luveltamab tazevibulin advancing to Phase 2/3 in ovarian cancer with Phase 2 lung cancer program demonstrates clinical validation of platform
Public company stability: NASDAQ-listed (STRO) with $190M cash runway as of FY2025, providing career visibility and equity upside potential

Watch Out For

Burning cash rapidly: R&D spend nearly doubled YoY ($137M to $252M in FY2025) while revenue declined ($68M to $62M), creating sustainability pressure—burn rate suggests ~9 months of runway at current spending
No commercial revenue stream: all programs remain preclinical to Phase 2; company depends entirely on catalyst-driven valuation with no approved products to generate operating cash flow
Zero current hiring: active job count of 0 indicates company is not actively recruiting, suggesting resource constraints or restructuring phase

Generated by Claude from Sutro Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

STRO-001

B-cell Lymphoma

PHASE_1

Clinical Trials (1)

NCT03424603Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Phase 1

STRO-002

Ovarian Cancer

PHASE_1

Clinical Trials (1)

NCT03748186Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Phase 1

STRO-004

Head and Neck Squamous Cell Carcinoma HNSCC

PHASE_1

Clinical Trials (1)

NCT07227168A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Phase 1

Luveltamab tazevibulin

Acute Myeloid Leukemia (AML)

PHASE_1_2

Clinical Trials (1)

NCT06679582Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

Phase 1/2

STRO-002

Neoplasm Malignant

PHASE_1_2

Clinical Trials (1)

NCT06238687A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

Phase 1/2

Luveltamab tazevibulin

Lung Cancer

PHASE_2

Clinical Trials (1)

NCT06555263Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2

Luveltamab tazevibulin

Ovarian Cancer

PHASE_2_3

Clinical Trials (1)

NCT05870748REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Top TAs: Oncology

H-1B (2023): 4 approvals

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

8 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$62M8%

R&D Spend

$252M(406%)84%

Net Income

-$227M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2025-09-29

1 employees affected— Remote Remote CA 94080, CA

source

2025-03-13

62 employees affected— 870 Industrial Road San Carlos CA 94070, CA

source

Source: state DOL filings, aggregated via Big Local News

No FDA warnings or WARN Act filings detected; primary risk remains financial runway and pipeline execution rather than regulatory or operational distress.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo